Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis – a Matched Case Control Study
Dr. Ashutosh Wechalekar
National Amyloidosis Centre
University College London
London, United Kingdom
Survival of patients with cardiac AL amyloidosis remains poor due to high mortality in the first 6-12 months. Rapidly effective regimes such as CyBorD are unable to overcome poor prognosis in very advanced AL amyloidosis (Venner et al and Palladini et al Leukemia 2014). The median survival of moderately advanced AL is ~60% at 2 years with CyBorD (Palladini et al Blood 2015). Last year, we reported a small series suggesting that oral doxycycline improves survival in cardiac AL amyloidosis (Wechalekar et al ASH abstract 2014) based on the possible cardio-protective effect of doxycycline on the heart from toxic amyloidogenic light chains. We now report a larger cohort confirming those findings.
https://ash.confex.com/ash/2015/webprogram/Paper85632.html